NCT01708161View on ClinicalTrials.gov

A Phase Ib/II Study of the Combination of BYL719 Plus AMG 479 in Adult Patients With Selected Solid Tumors

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

47

Participants

Timeline

Start Date

November 27, 2012

Primary Completion Date

December 26, 2014

Study Completion Date

June 1, 2017

Conditions
PIK3CA Mutated Advanced Solid TumorsPIK3CA Amplified Advanced Solid Tumors
Interventions
DRUG

BYL719

BYL719 is a small molecule inhibiting PI3-Kinase.

DRUG

AMG 479

AMG 479 is a monoclonal antibody directed against IGF1-R.

Trial Locations (10)

3000

Novartis Investigative Site, Leuven

10017

Novartis Investigative Site, New York

28033

Novartis Investigative Site, Madrid

28041

Novartis Investigative Site, Madrid

37203

Novartis Investigative Site, Nashville

41013

Novartis Investigative Site, Seville

90095

Novartis Investigative Site, Los Angeles

02114

Novartis Investigative Site, Boston

M5G 1Z6

Novartis Investigative Site, Toronto

08035

Novartis Investigative Site, Barcelona

Sponsors

Collaborators (1)

NantCell, Inc.
All Listed Sponsors
collaborator

NantCell, Inc.

INDUSTRY

lead

Novartis Pharmaceuticals

INDUSTRY

NCT01708161 - A Phase Ib/II Study of the Combination of BYL719 Plus AMG 479 in Adult Patients With Selected Solid Tumors | Biotech Hunter | Biotech Hunter